Biography

James I. Geller, MD, started in the Division of Oncology at Cincinnati Children's Hospital Medical Center as an assistant professor within the UC Department of Pediatrics in 2004. Currently, he is the medical director of Liver and Renal Tumor Programs and co-director of the Retinoblastoma Program.

His primary academic interest is the development of novel therapy options for infants, children, adolescents and young adults with solid tumors. At the institutional level, he achieves this through direct patient care and by leading our teams in clinical and research efforts in my specialty areas at Cincinnati Children’s Hospital Medical Center. At the national level, he participates as a member of the Children’s Oncology Group (COG) Renal Tumor (RTC), Liver Tumor, Retinoblastoma and Central Nervous System Committees; He functions as vice chair for the RTC and liaison to the COG Developmental Therapeutics Committee (DVL) and Pediatric Preclinical Testing Program as well as chair both the RTC Developmental Therapeutics Working Group and the COG High Risk Renal Tumors Protocols including AREN1721 (focused on immunotherapy and anti-angiogenic therapy for TFE Renal Cell Carcinoma), AREN1921 (focused on relapsed and anaplastic Wilms tumor), and has drafted the next concept for study of epigenetic therapy plus chemotherapy for treatment of rhabdoid tumor. He also serves as co-chair of the COG liver tumor protocol, the Pediatric Hepatic International Tumor Trial (PHITT); AHEP1531.

It is his goal to help facilitate the development of novel therapy for young patients affected with solid tumors. Current areas of expansion include the establishment of the Translational RCC Research Initiatives including a registry for TFE RCC, and development of data harmonization and treatment optimization for relapsed pediatric liver cancers. Integration of cellular and immunotherapy, as well as novel interventional therapeutics, remains a priority.